Search
Menu
Home
HTB
2017
October
October 2017
Contents
Editorial
September/October 2017: Volume 18 Number 9/10
New guides to PrEP
Special reports
Experts disagree with controversial BMJ support for older HIV drugs in pregnancy
The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk
Conference reports
9th IAS Conference on HIV Science (IAS 2017)
Dual therapy with darunavir/r plus lamivudine as first-line ART
Dual therapy with dolutegravir plus lamivudine as first-line ART
Once-daily raltegravir: 96-week results from the ONCEMRK study
New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex
On-demand dosing for PrEP is highly effective in French expanded access programme
Psychological impact of PrEP: beyond efficacy and cost-effectiveness
Early ART and testing HIV negative with rapid HIV tests
Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris
Antiretrovirals
Gilead uses voucher to speed FDA review of bictegravir
Treatment access
Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries
UK donates well to the Global Fund, but slashed bilateral aid for HIV
Dozens of countries left out of new PEPFAR strategy, threatening the global AIDS response
NHS access to PrEP in the UK: country update
Generic PrEP in France and Scotland challenges access across the UK
Pregnancy
BHIVA challenges BMJ recommendations on ART during pregnancy: tenofovir still strongly recommend
Guidelines
UK PrEP guidelines: online for comment (Oct 2017)
US IDSA HIV pain management guidelines (2017)
Side effects
Increased frequency and progression of kidney disease in HIV positive people
Coinfections and complications
Enhanced OI prophylaxis reduces mortality when starting ART late
HIV prevention and transmission
PrEP use in adolescent gay and bisexual men: US study shows need for easier access and easier PrEP
Other news
STOPAIDS reviews DFID’s work on HIV and AIDS
On the web
HIV and drug adherence: RITA!
PDFs
September/October 2017: Volume 18 Number 9/10
HTB RSS
Early access
CROI 2025: Introduction to this year’s conference
9 March 2025
CROI 2025: Stand up for science rally against Trump funding freeze
9 March 2025
CROI 2025: Jay Bhattacharya is proposed to head the US NIH which would further wreck global science
7 March 2025
All early access reports
Current issues
March 2025
February 2025
January 2025
Back issues
Special report
Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer
1 March 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate